Advertisement

ADVERTISEMENT

Breast Cancer

Rebecca Shatsky, MD, University of California, San Diego
Videos
Datopotamab Deruxtecan Plus Durvalumab for Certain Patients With Advanced Breast Cancer
06/07/2024
Rebecca Shatsky, MD
Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.
Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.
Rebecca Shatsky, MD, shares...
06/07/2024
Oncology
Matthew Goetz, MD, Mayo Clinic
VIDEOS
Lasofoxifene vs Fulvestrant for ESR1-Mutated Metastatic Breast Cancer With Progression on CDK4/6 Inhibitors
09/15/2022
Matthew Goetz, MD, highlights findings from the ELAINE 1 trial exploring lasofoxifene vs fulvestrant for patients with ESR1-mutated locally advanced or metastatic breast cancer who progressed on aromatase and CDK4/6 inhibitors.
Matthew Goetz, MD, highlights findings from the ELAINE 1 trial exploring lasofoxifene vs fulvestrant for patients with ESR1-mutated locally advanced or metastatic breast cancer who progressed on aromatase and CDK4/6 inhibitors.
Matthew Goetz, MD, highlights...
09/15/2022
Oncology
Matthew Goetz, MD, Mayo Clinic
VIDEOS
Abemaciclib Added to a Nonsteroidal Aromatase Inhibitor Improves OS in HR-Positive, HER2-Negative Breast Cancer
09/14/2022
Matthew Goetz, MD, discusses a second interim analysis on OS results for the MONARCH 3 trial, demonstrating prolonged OS with the addition of abemaciclib to a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative...
Matthew Goetz, MD, discusses a second interim analysis on OS results for the MONARCH 3 trial, demonstrating prolonged OS with the addition of abemaciclib to a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative...
Matthew Goetz, MD, discusses a...
09/14/2022
Oncology
Sara Tolaney, MD, Dana-Farber Cancer Institute
VIDEOS
Amcenestrant vs Physician’s Choice of Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
09/13/2022
Sara Tolaney, MD, discusses results from AMEERA-3, an open-label randomized phase 2 trial that explored amcenestrant vs physician’s choice of endocrine therapy in patients with endocrine-resistant ER-positive, HER2-negative advanced breast...
Sara Tolaney, MD, discusses results from AMEERA-3, an open-label randomized phase 2 trial that explored amcenestrant vs physician’s choice of endocrine therapy in patients with endocrine-resistant ER-positive, HER2-negative advanced breast...
Sara Tolaney, MD, discusses...
09/13/2022
Oncology
DrL
Podcasts
Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part II
03/15/2022
In part two of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.
In part two of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.
In part two of this interview,...
03/15/2022
Oncology
Dr L
Podcasts
Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part I
03/14/2022
In part one of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.
In part one of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.
In part one of this interview,...
03/14/2022
Oncology
Elisa Agostinetto, MD
Videos
Tackling Technical Assessment Challenges in HER2-Low BC Space
02/28/2022
In part 4 of this series, Elisa Agostinetto, MD, Institut Jules Bordet, discusses the challenges of technical assessment in the HER2-low breast cancer treatment space.
In part 4 of this series, Elisa Agostinetto, MD, Institut Jules Bordet, discusses the challenges of technical assessment in the HER2-low breast cancer treatment space.
In part 4 of this series, Elisa...
02/28/2022
Oncology
Dr Agostinetto
Videos
Future Developments in HER2-Low BC Featuring Dr Agostinetto
02/28/2022
In part three of this series, Dr Agostinetto, Institut Jules Bordet, highlights future trial developments in the HER2-low breast cancer space such as DESTINY-breast-04, DESTINY-breast-06, and DEBBRAH study.
In part three of this series, Dr Agostinetto, Institut Jules Bordet, highlights future trial developments in the HER2-low breast cancer space such as DESTINY-breast-04, DESTINY-breast-06, and DEBBRAH study.
In part three of this series, Dr...
02/28/2022
Oncology
Elisa Agostinetto, MD, Institut Jules Bordet
Videos
Promising New Therapies for HER2-Low Breast Cancer
02/28/2022
In part 2 of this series, Dr Agostinetto, Institut Jules Bordet, discusses several effective, promising agents in HER2-low breast cancer treatment.
In part 2 of this series, Dr Agostinetto, Institut Jules Bordet, discusses several effective, promising agents in HER2-low breast cancer treatment.
In part 2 of this series, Dr...
02/28/2022
Oncology
Sara Hurvitz, MD, Discusses Trials on Tucatinib Therapy for HER2+ Metastatic Breast Cancer
Videos
Sara Hurvitz, MD, Discusses Trials on Tucatinib Therapy for HER2+ Metastatic Breast Cancer
11/28/2021
Dr Hurvitz discusses the HER2CLIMB and HER2CLIMB-02 trials examining tucatinib's activity and safety in patients with HER2-positive metastatic breast cancer.
Dr Hurvitz discusses the HER2CLIMB and HER2CLIMB-02 trials examining tucatinib's activity and safety in patients with HER2-positive metastatic breast cancer.
Dr Hurvitz discusses the...
11/28/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use